Clinical Trials Logo

Clinical Trial Summary

Observation of a cohort of 400 patients with different types of lymphomas.


Clinical Trial Description

A database on 400 patients diagnosed with lymphomas was built up over 20 years at Nîmes University Hospital. Biopsies were made on these tumours and all the samples were frozen. Considering the heterogeneous nature of lymphomas, randomized clinical trials based on very precise criteria for the inclusion or non-inclusion of patients are the gold standard for studying the various sub-types of lymphomas by concentrating on homogeneous populations for which a limited number of parameters are analyzed simultaneously. However, due to the complexity of their medical situation, many patients may be excluded form these trials, thus making it difficult to obtain reliable results. The analysis of a non-selected cohort has two main advantages: (1) to better understand the diversity of patients with lymphomas for which the recommendations are constantly evolving and (2) to analyze how, exactly, these are managed by integrating points which are currently poorly evaluated such as comorbidities and accessibility to treatment. The aim of the study is to describe how these patients are managed and to demonstrate that not all patients are able to benefit from the official management recommendations applicable to their pathology. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04947618
Study type Observational
Source Centre Hospitalier Universitaire de Nimes
Contact Eric JOURDAN, Dr.
Phone 0466684033
Email eric.jourdan@chu-nimes.fr
Status Recruiting
Phase
Start date January 22, 2024
Completion date January 31, 2026

See also
  Status Clinical Trial Phase
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Completed NCT00600353 - Multi-day Doses in Prevention of Nausea and Emesis Phase 2
Completed NCT01432951 - A Study of Enzastaurin in Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma Phase 1
Terminated NCT02440685 - A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors Phase 1/Phase 2
Completed NCT02249429 - Open-Label, Non Randomized Phase 2 Study With Safety Run-In Phase 2
Active, not recruiting NCT02732275 - DS-3201b in Participants With Lymphomas Phase 1
Completed NCT00509184 - Rituximab and Involved Field Radiotherapy in Early Stage Follicular Lymphoma Phase 2
Recruiting NCT00619879 - Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies Phase 3
Completed NCT00146055 - Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood Phase 2
Completed NCT00741871 - A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies Phase 1
Recruiting NCT02441972 - Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics Phase 1
Completed NCT00078637 - Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or Lymphoma Phase 1
Withdrawn NCT03359733 - A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor Phase 1
Completed NCT00037791 - Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia Phase 3
Completed NCT01388335 - A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin Phase 1